Angiogenic Cytokines and Fibrinolytic Activity in Parapneumonic Effusions
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT01325454|
Recruitment Status : Unknown
Verified March 2011 by Taipei Medical University Hospital.
Recruitment status was: Recruiting
First Posted : March 29, 2011
Last Update Posted : March 29, 2011
|Condition or disease||Intervention/treatment|
|Pleural Effusion||Device: pleural pigtail drainage|
|Study Type :||Observational|
|Estimated Enrollment :||80 participants|
|Observational Model:||Case Control|
|Official Title:||Angiogenic Cytokines and Fibrinolytic Activity in Parapneumonic Effusions|
|Study Start Date :||January 2008|
|Estimated Primary Completion Date :||June 2011|
|Estimated Study Completion Date :||December 2011|
Patients with parapneumonic effusions
Patients with pleural effusions of unknown causes admitted to Taipei Medical University Hospital were included if parapneumonic effusion was diagnosed as one associated with pneumonia according to the criteria of the American Thoracic Society (ie, patients with newly acquired respiratory symptoms, fever, and abnormal breath sounds, plus a new lung infiltrate seen on a chest radiograph).
Device: pleural pigtail drainage
With the guidance of chest US, 50 ml of pleural fluid was collected using a standard thoracentesis technique immediately or within 24 hr after hospitalization. When pleural effusion was multi-loculated, the fluid was aspirated from the largest loculus. Routine analyses of pleural fluid for total leukocytes, cell differentials of leukocytes, pH value, and levels of protein, glucose and LDH were performed in addition to cytological and microbiologic examination of pleural fluid.The rest of pleural fluid samples were mixed with 3.8 % sodium citrate in a 9:1 ratio of pleural fluid to citrate. The sodium citrate-mixed pleural fluid specimens were immersed in ice immediately and then centrifuged at 2,500 g for 10 minutes. The cell-free supernatants of pleural fluid were frozen at -70℃ immediately after centrifuge for later measurements. The commercially available enzyme-linked immunosorbent assay kits were used to measure the effusion levels of VEGF, IL-8 , tPA and PAI-1.
- Response to treatment including improvement in vital signs and chest radiography [ Time Frame: 5 days after treatment within admission ]
- Chest radiography and pulmonary function testing with spirometry. [ Time Frame: At discharge, and at 6 months ]
Biospecimen Retention: Samples Without DNA
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01325454
|Division of Pulmonary Medicine, Taipei Medical University Hospital||Recruiting|
|Taipei, Taiwan, 110|
|Contact: Chi-Li Chung, MD, PhD 886-2-27372181 ext 3903 firstname.lastname@example.org|
|Principal Investigator: Chi-Li Chung, MD, PhD|
|Sub-Investigator: Shih-Hsin Hsiao, MD|
|Principal Investigator:||Chi-Li Chung, MD, PhD||Division of Pulmonary Medicine, Taipei Medical University, Taipei, Taiwan|